{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:12:28Z","timestamp":1794600748197,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity. Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions. In addition, prognostic markers are greatly needed for the randomization in clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to test the ALS Functional Rating Scale-Revised (ALSFRS-R) progression rate (\u0394FS) as a prognostic marker of survival in a Danish ALS cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The ALSFRS-R score at test date in association with duration of symptoms, from the onset of symptoms until test date, (defined as \u0394FS\u2019) was calculated for 90 Danish patients diagnosed with either probable or definite sporadic ALS. Median survival time was then estimated from the onset of symptoms until primary endpoint (either death or tracheostomy). \u0394FS\u2019 was subjected to survival analysis using Cox proportional hazards modelling, log-rank test, and Kaplan-Meier survival analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results and conclusions<\/jats:title>\n                <jats:p>Both \u0394FS\u2019 and age was found to be strong predictors of survival of the Danish ALS cohort. Both variables are easily obtained at the time of diagnosis and could be used by clinicians and ALS patients to plan future supportive and palliative treatment. Furthermore, \u0394FS\u2019, is a simple, prognostic marker that predicts survival in the early phase of disease as well as at later stages of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02187-8","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T09:03:03Z","timestamp":1618650183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Anne-Lene","family":"Kj\u00e6ldgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Pilely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten Skovgaard","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Hedegaard","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne \u00d8berg","family":"Lauritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W\u00f8rlich","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Svenstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Karlsborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Thagesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Blaabjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sta","family":"The\u00f3d\u00f3rsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Gundtoft","family":"Elmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette Torvin","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Bonefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Garred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"issue":"11","key":"2187_CR1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1474-4422(07)70265-X","volume":"6","author":"J Phukan","year":"2007","unstructured":"Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994\u20131003. https:\/\/doi.org\/10.1016\/S1474-4422(07)70265-X.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2187_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000351153","volume":"41","author":"A Chio","year":"2013","unstructured":"Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118\u201330. https:\/\/doi.org\/10.1159\/000351153.","journal-title":"Neuroepidemiology"},{"issue":"5\u20136","key":"2187_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chio","year":"2009","unstructured":"Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5\u20136):310\u201323. https:\/\/doi.org\/10.3109\/17482960802566824.","journal-title":"Amyotroph Lateral Scler"},{"key":"2187_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","volume":"9","author":"K Poesen","year":"2018","unstructured":"Poesen K, Van Damme P. Diagnostic and prognostic performance of Neurofilaments in ALS. Front Neurol. 2018;9:1167.","journal-title":"Front Neurol"},{"issue":"1\u20132","key":"2187_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","volume":"169","author":"JM Cedarbaum","year":"1999","unstructured":"Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169(1\u20132):13\u201321. https:\/\/doi.org\/10.1016\/S0022-510X(99)00210-5.","journal-title":"J Neurol Sci"},{"issue":"10","key":"2187_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","volume":"257","author":"PH Gordon","year":"2010","unstructured":"Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257(10):1713\u20137. https:\/\/doi.org\/10.1007\/s00415-010-5609-1.","journal-title":"J Neurol"},{"issue":"1","key":"2187_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1212\/01.WNL.0000148648.38313.64","volume":"64","author":"P Kaufmann","year":"2005","unstructured":"Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64(1):38\u201343. https:\/\/doi.org\/10.1212\/01.WNL.0000148648.38313.64.","journal-title":"Neurology"},{"issue":"2","key":"2187_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","volume":"66","author":"F Kimura","year":"2006","unstructured":"Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000194316.91908.8a.","journal-title":"Neurology"},{"issue":"6","key":"2187_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00415-015-7731-6","volume":"262","author":"M Elamin","year":"2015","unstructured":"Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015;262(6):1447\u201354. https:\/\/doi.org\/10.1007\/s00415-015-7731-6.","journal-title":"J Neurol"},{"issue":"10","key":"2187_CR10","first-page":"1023","volume":"59","author":"H Nodera","year":"2007","unstructured":"Nodera H, Izumi Y, Kaji R. New diagnostic criteria of ALS (Awaji criteria). Brain Nerve. 2007;59(10):1023\u20139.","journal-title":"Brain Nerve"},{"issue":"5","key":"2187_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293\u20139. https:\/\/doi.org\/10.1080\/146608200300079536.","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"2187_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1136\/jnnp-2015-310998","volume":"87","author":"J Labra","year":"2016","unstructured":"Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628\u201332. https:\/\/doi.org\/10.1136\/jnnp-2015-310998.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2187_CR13","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1212\/01.wnl.0000243812.25517.87","volume":"67","author":"PH Gordon","year":"2006","unstructured":"Gordon PH, Cheung YK. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;67(7):1314\u20135 author reply \u22125.","journal-title":"Neurology"},{"key":"2187_CR14","doi-asserted-by":"publisher","unstructured":"van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2021:1\u20138. https:\/\/doi.org\/10.1080\/21678421.2021.1879865.","DOI":"10.1080\/21678421.2021.1879865"},{"issue":"5","key":"2187_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.neurol.2017.03.018","volume":"173","author":"A Verschueren","year":"2017","unstructured":"Verschueren A. Motor neuropathies and lower motor neuron syndromes. Rev Neurol. 2017;173(5):320\u20135.","journal-title":"Rev Neurol"},{"issue":"5","key":"2187_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","volume":"17","author":"HJ Westeneng","year":"2018","unstructured":"Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(18)30089-9.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2187_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/acn3.550","volume":"5","author":"JD Berry","year":"2018","unstructured":"Berry JD, Taylor AA, Beaulieu D, Meng L, Bian A, Andrews J, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5(4):474\u201385. https:\/\/doi.org\/10.1002\/acn3.550.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2187_CR18","doi-asserted-by":"publisher","first-page":"13378","DOI":"10.1038\/s41598-020-70125-8","volume":"10","author":"V Grollemund","year":"2020","unstructured":"Grollemund V, Chat GL, Secchi-Buhour MS, Delbot F, Pradat-Peyre JF, Bede P, et al. Development and validation of a 1-year survival prognosis estimation model for amyotrophic lateral sclerosis using manifold learning algorithm UMAP. Sci Rep. 2020;10(1):13378. https:\/\/doi.org\/10.1038\/s41598-020-70125-8.","journal-title":"Sci Rep"},{"issue":"8","key":"2187_CR19","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.clinph.2020.04.005","volume":"131","author":"JM Shefner","year":"2020","unstructured":"Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975\u20138. https:\/\/doi.org\/10.1016\/j.clinph.2020.04.005.","journal-title":"Clin Neurophysiol"},{"issue":"6","key":"2187_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/mus.26042","volume":"57","author":"NJ Thakore","year":"2018","unstructured":"Thakore NJ, Lapin BR, Pioro EP. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve. 2018;57(6):937\u201345. https:\/\/doi.org\/10.1002\/mus.26042.","journal-title":"Muscle Nerve"},{"issue":"1","key":"2187_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2018.07.012","volume":"132","author":"LA Foster","year":"2019","unstructured":"Foster LA, Salajegheh MK. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med. 2019;132(1):32\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2018.07.012.","journal-title":"Am J Med"},{"issue":"8","key":"2187_CR22","doi-asserted-by":"publisher","first-page":"e037753","DOI":"10.1136\/bmjopen-2020-037753","volume":"10","author":"AL Kj\u00e6ldgaard","year":"2020","unstructured":"Kj\u00e6ldgaard AL, Pilely K, Olsen KS, Lauritsen A, Pedersen SW, M\u00f8ller K, et al. Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan. BMJ Open. 2020;10(8):e037753. https:\/\/doi.org\/10.1136\/bmjopen-2020-037753.","journal-title":"BMJ Open"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02187-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T21:04:05Z","timestamp":1618693445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02187-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2187"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02187-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This cohort study was retrospectively carried out in a prospectively included cohort of ALS patients who participated in an explorative study with a focus on the innate immune system. The protocol for the prospective study was registered on Clinicaltrials.gov (NCT02869048) and has been previously published []. The Committees on Health Research Ethics in the Capital Region of Denmark (Approval number H-16017145) and the Danish Data Protection Agency (File number 2012-58-0004) approved the study and written informed consent was obtained from all the participants. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}